@entity808 are the most common @entity5 of cranial nerves. @entity808 are very rare @entity5 , accounting for approximately 10% of @entity932 . Standard treatment is complete surgical resection if possible. The role of fractionated stereotactic radiotherapy remains to be defined. Thirteen @entity1 with cranial @entity808 underwent fractionated stereotactic radiotherapy. Seven @entity1 had trigeminal @entity808 , three @entity808 of the lower cranial nerves, and three located in the cerebellopontine angle without involvement of the acoustic nerve. Treatment included primary or adjuvant radiotherapy in progressive disease. @entity5 volume ranged from 4.5 to 76.0 cc (median 19.8 cc). Median dose was 57.6 Gy with 1.8 Gy/fraction. Median follow-up was 33 months (range 13-70 months). @entity5 control rate was 100% (13/13). @entity5 size remained stable in nine @entity1 and decreased in four. Improvement of preexisting @entity51 was seen in four cases. No @entity1 developed new @entity129 . No @entity1 showed clinically significant complications of irradiation. Fractionated stereotactic radiotherapy is an effective and well-tolerated noninvasive treatment for cranial @entity808 with excellent @entity5 control rates. It is an option for @entity1 at higher risk for microsurgical resection or in residual and recurrent @entity5 .

Management of benign cranial XXXX by fractionated stereotactic radiotherapy.

@entity808 :: ('MESH:D009442', 'Disease') :: ['nonacoustic schwannomas', 'Schwannomas', 'schwannomas', 'Nonacoustic schwannomas'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial nerve or brain stem deficits'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial schwannomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'Local tumor', 'tumors'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficits']
@entity808 :: (MESH:D009442,Disease) :: ['nonacoustic schwannomas']
